Suggested remit - To appraise the clinical and cost effectiveness of ivosidenib within its marketing authorisation for treating adults with relapsed or refractory acute myeloid leukaemia which is isocitrate dehydrogenase-1 mutation-positive
 
Status In progress
Process STA 2018
ID number 1548

Provisional Schedule

Scoping workshop (London) 03 December 2019 (14:00)
Expected publication 02 December 2020

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
18 October 2019 - 15 November 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 March 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.
22 March 2019 Proposed, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.
22 March 2019 In progress, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance